Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent.~* Must be 18 years at time of signing the informed consent form.~* Willing to participate in all required evaluations and procedures in the study including the ability to swallow pills without difficulty.~* Patients must have a diagnosis of DM based upon the characteristic cutaneous findings proposed by Sontheimer\[6\] and/or a skin biopsy consistent with DM.~* Patients must be candidate for systemic therapy for their DM skin disease defined by inadequate response to aggressive sun protection along with the use of potent topical corticosteroids and/or immunomodulators.~* Patients with a diagnosis of dermatomyositis on steroid-sparing agent and/or systemic steroids (maximum dose of prednisone 1mg/Kg) and still having cutaneous disease activity of at least 5 on the CDASI scale.~* If on immunosuppressive treatments and/or steroids, patients must be on stable doses for at least 4 weeks (28 days).~* Patients must undergo age appropriate cancer screening.~* Females of childbearing potential (FCBP) must have a negative pregnancy test at screening (day 0 of the study and every month throughout the study). While on investigational product and for at least 28 days after taking the last dose of investigational product.~Exclusion Criteria:~* Increasing or changing dose of topical therapy within 14 days of study day 0 (including but not limited to topical corticosteroids, tacrolimus, pimecrolimus).~* Increasing or changing systemic steroids dosing within 28 days of study day 0.~* Increasing or changing dosing for concurrent therapy agents within 28 days or 5 half-lives of the biologic agent, whichever is longer, before study day 0: methotrexate, azathioprine, mycophenolate mofetil, hydroxychloroquine, dapsone, leflunomide, cyclosporine, biologic agents (anti-TNFs), IVIG, rituximab.~* History of any clinically significant (as determined by the investigators) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.~* Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* Pregnant or breastfeeding.~* Untreated Latent Mycobacterium tuberculosis infection or active tuberculosis infection as indicated by a positive Purified Protein Derivative (PPD) skin test or T-spot.~* Any condition, including the presence of laboratory abnormalities that places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* Patients with acute dermatomyositis onset and rapid progression of muscle disease or significant systemic involvement including pulmonary diseases associated with DM.~* Prior major surgery or major life-threatening medical illness within 2 weeks.~* Inflammatory bowel disease, malabsorption or any other gastrointestinal motility disorders that limit the absorption of the study drug.~* Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity.~* Prior history of suicide attempt at any time in the patient's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.~* Active substance abuse or a history of substance abuse within 6 months prior to screening.~* Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).~* Prior treatment with apremilast.~* Any severe systemic illness requiring IV antibiotics within the two weeks prior to initiation of the study drug.~* Malignancy or history of malignancy within the past four years, except for:~  * treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas;~ * treated \[ie, cured\] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 4 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dermatomyositis patients with refractory cutaneous disease (Type: EXPERIMENTAL): Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete